Citations

Clear

2117 citation(s) found for "Mayo, Steven".

SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.
Hong, Angela , Schuetze, Scott M. , Wagner, Andrew J. , Attia, Steven , Bae, Susie , Tine, Brian Andrew Van, Freeman, Carolyn, Brigman, Brian E. , Kirsch, David G. , Mowery, Yvonne Marie , Ballman, Karla V. , Monga, Varun , Heise, Rachel S. , Choy, Edwin , Burgess, Melissa , Pryor, David I. , Tinoco, Gabriel , Chmielowski, Bartosz , Rijn, Matt van de , Riedel, Richard F.

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11504-11504

10.1200/jco.2024.42.16_suppl.11504 Get It

11504 Background: Surgery & radiation therapy (RT) yield high local control rates for soft tissue sarcoma (STS) of the extremity and limb girdle. However, patients (pts) with high-grade stage III STS are at significant risk for developing metastasis. Median survival for pts with metastatic STS is < 2 years. SARC028 (NCT02301039) evaluated the efficacy of pembrolizumab (pembro) for metastatic STS, showing 20% and 8.7% response rates in undifferentiated pleomorphic sarcoma (UPS) and pleomorphic/dedifferentiated liposarcoma (LPS), respectively. We hypothesized that neoadjuvant pembro with concurrent RT followed by surgery and adjuvant pembro for stage III UPS, including myxofibrosarcoma, or LPS would stimulate an anti-tumor immune response to eliminate micrometastatic disease & improve disease-free survival (DFS). SU2C-SARC032 (NCT03092323) is a multi-institutional, international, randomized phase 2 trial evaluating the safety and efficacy of adding pembro to standard of care (SOC) RT & surgery for pts with stage III UPS or LPS. Methods: Pts aged > 12 yo with stage III (FNCLCC grade 2 or 3) UPS or LPS of the extremity and limb girdle were enrolled. Pts were randomized (1:1, stratified by grade) to neoadjuvant RT (50 Gy/25 fx) then surgery (SOC arm) or neoadjuvant pembro and RT then surgery & adjuvant pembro (EXP arm). Pembro was given 200 mg IV Q3 wk for 3 doses (before, during & after RT) & up to 14 adjuvant cycles. The primary endpoint was 2-yr DFS. Secondary endpoints included local recurrence-free survival (LRFS), distant disease-free survival (DDFS), & overall survival (OS). Target enrollment of 126 evaluable patients (max 144 total) provided 80% power (1-sided α = 0.05) to distinguish between a null hypothesis of 50% 2-yr DFS rate & alternative hypothesis of 75% 2-yr DFS rate by log-rank test, with initial analysis at 45 DFS events. Cox models were stratified by grade; primary analysis was a one-sided stratified log-rank test. Results: Between July 2017-November 2023, 143 patients were enrolled, predominantly with UPS (85%) & grade 3 (64%) histology. Median follow-up for alive patients is 24.1 mo. DFS in the EXP arm is significantly higher than the SOC arm (p = 0.023; HR 0.57, 90% CI: 0.35, 0.91). Estimated 2-yr DFS is 53% (90% CI: 43, 66%) for SOC vs 70% (90% CI: 61, 81%) for EXP arm. Currently, there is no statistically significant difference in LRFS (HR 0.55, 95% CI: 0.21, 1.42), DDFS (HR 0.57, 95% CI: 0.32, 1.01), or OS (HR 0.39, 95% CI: 0.14, 1.12). Pts with grade 3 sarcomas had improved DFS with pembro (HR 0.47, 95% CI: 0.25, 0.89), but no difference in DFS was observed in grade 2 tumors (HR 1.21, 95% CI: 0.35, 4.18). The proportion of patients with grade 3+ adverse events was significantly higher in EXP (52%) vs SOC arm (26%) (p = 0.002). Conclusions: Theaddition of neoadjuvant & adjuvant pembro to RT and surgery significantly improves DFS for pts with stage III UPS and LPS of the extremity and limb girdle. Clinical trial information: NCT03092323 .
Outcomes of non‐angiosarcoma radiation‐associated soft tissue sarcomas of the chest
GARAYUA-CRUZ, LEILANI, Broida, Samuel E. , Okuno, Scott H. , Welliver, M.X., Wilke, Benjamin K. , Goulding, Krista , Rose, Peter S. , Houdek, Matthew T. , Welliver, Meng Xu, Wilke, B K , Goulding, Krista , Houdek, Matthew T , Broida, Samuel E , Robinson, Steven I. , Siontis, Brittany L.

Mayo Clinic

Journal of Surgical Oncology | June 12, 2024 | Volume: 130 | Issue: 1 | Pages: 56-63

10.1002/jso.27686 | PMID 38864186 Get It

Abstract Background Radiation‐associated soft tissue sarcomas (RA‐STS) are rare complications of patients receiving radiation therapy (RT) and are generally associated with a poor prognosis. Most of the literature surrounding RA‐STS of the chest is centered on angiosarcoma. Therefore, we aim to document the management and outcome of patients with non‐angiosarcoma RA‐STS of the chest. Methods We reviewed 17 patients (all female, median age 65 years) diagnosed with RA‐STS. The most common primary malignancy was breast carcinoma ( n = 15), with a median RT dose of 57.9 Gy. All patients underwent surgical resection; five patients (29%) received radiotherapy; and five patients (29%) received peri‐operative chemotherapy. Results The 5‐year local recurrence and metastatic‐free survival were 61% and 60%, while the 5‐year disease‐specific survival was 53%. Local recurrence was associated with death due to disease (HR 9.06, p = 0.01). Complications occurred in nine of patients, most commonly due to a wound complication ( n = 7). At the most recent follow‐up, the median Musculoskeletal Tumor Society Score was 63%. Conclusion RA‐STS involving the chest wall are aggressive tumors with a high risk of local relapse and death due to disease. Local recurrence was associated with death due to disease; as such, we recommend aggressive surgical management with evaluation for adjuvant therapies.
Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
Tap, William D. , Somaiah, Neeta , Razak, Albiruni Ryan Abdul, Reichardt, Peter , Druta, Mihaela , Singh, Arun S. , Attia, Steven , Moynihan, Kevin, Lawrence, Julia, Wagner, Andrew J. , Kang, Yoon‐Koo , Garrido, Marcelo , Desar, Ingrid M.E. , Italiano, Antoîne , Wilky, Breelyn A , Heinrich, Michael C. , Bauer, Sebastian , Serrano, César , Trent, Jonathan C.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS11588-TPS11588

10.1200/jco.2024.42.16_suppl.tps11588 Get It

TPS11588 Background: Imatinib is the worldwide standard for first-line therapy of advanced KIT-mutant GIST. However, secondary resistance mutations in the KIT ATP-binding domain (exons 13, 14), activation loop (exons 17, 18), or both develop and result in loss of imatinib-sensitivity. Bezuclastinib has a highly selective inhibition profile, leading to minimal off-target toxicities and allowing for combination with sunitinib. While no single tyrosine kinase inhibitor (TKI) inhibits all KIT mutations, the combination of bezuclastinib + sunitinib targets commonly occurring primary (exons 9, 11) and secondary (exons 13, 14, 17, and 18) KIT mutations and may provide more durable responses. The early signs of clinical activity, tolerability, and safety observed with the combination thus far in Peak Part 1 (Somaiah et al. [presentation] CTOS 2023. Paper 62) are consistent with the completed Phase 1/2 study (PLX121-01). Methods: Peak (NCT05208047) is a global, randomized, open-label, multi-part Phase 3 study evaluating the efficacy and safety of bezuclastinib + sunitinib versus sunitinib as second-line treatment in adult pts who were intolerant to imatinib or whose tumors had imatinib-resistance. Current Peak study sites are located in North America (3 countries), South America (3 countries), Europe (12 countries), and Asia-Pacific (4 countries). The lead-in portion to test a new formulation of bezuclastinib, (Part 1) completed enrollment in April 2023. Based upon PK and safety, a dose of bezuclastinib 600 mg QD + sunitinib 37.5 mg QD was determined for Part 2 of the Peak study. Part 2 will enroll ~388 pts to be randomized (1:1) to bezuclastinib 600 mg QD + sunitinib 37.5 mg QD or sunitinib 37.5 mg QD alone. Key inclusion: >1 measurable lesion per modified Response Evaluation Criteria in Solid Tumors (mRECIST) v1.1, Eastern Cooperative Oncology Group Performance Status 0-2, adequate organ function, and prior imatinib therapy (no other prior therapy). Key exclusion: known PDGFR mutations or succinate dehydrogenase deficiency, clinically significant cardiac disease, and use of strong CYP3A4 inhibitors or inducers. The primary endpoint is progression-free survival (PFS) confirmed by blinded independent central review per mRECIST v1.1. Additional efficacy (including overall survival and objective response rate) and safety endpoints will be evaluated and circulating tumor DNA (ctDNA) will be collected and assessed. Clinical trial information: NCT05208047 .
Clinical features, molecular findings, and clinical outcomes of follicular dendritic cell sarcoma.
Breen, William G. , Zanwar, Saurabh , Ruan, Gordon , Okuno, Scott H. , Garrity, James, Bennani, Nabila Nora, Abeykoon, Jithma P. , Yi, Dongni , Rech, Karen L. , Lester, Scott C. , Robinson, Steven I. , Siontis, Brittany L. , Kimball, Brittany , Ravindran, Aishwarya , Shah, Meera , Goyal, Gaurav , Go, Ronald S.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e23554-e23554

10.1200/jco.2024.42.16_suppl.e23554 Get It

e23554 Background: Follicular dendritic cell sarcoma (FDCS) is a low-grade neoplasm arising from follicular dendritic cells. Its diagnosis is challenging due to its extreme rarity, and the optimal management remains unknown. Methods: We conducted a retrospective study of FDCS patients (pts) seen at Mayo Clinic, MN since 2018. Time to event analyses were done from the time of diagnosis. Results: Ten pts with FDCS were identified (Table). The median age was 60 years (range, 38-76) and 5 were males. Abdominal pain was the most common presenting symptom (30%) followed by constitutional symptoms, shortness of breath, and vision change. In 3 pts, the diagnosis was incidental. The 2 most common primary locations were abdomen/pelvis (50%) and mediastinum (30%). Six pts (60%) presented with advanced disease and 3 (30%) had Castleman’s disease. Most (60%) had advanced disease. Six pts had Epstein-Barr virus in situ hybridization and all tested negative. Seven pts had next generation sequencing and 5 (83%) had genetic alterations detected with CDKN2A/B alterations being most frequent (3 pts, all with advanced disease). The median follow up was 4.3 years (range, 0.2-13.3). In the 4 patients with localized disease, 3 underwent complete surgical excision resulting in complete remissions (CRs). The one who received radiation had a partial remission (PR). The median time to progression after 1st line treatment was 4 months (all with advanced disease). All 3 pts who died had advanced disease and 2 had CDKN2A/B alterations. Conclusions: In FDCS, localized diseases managed by surgical excision with or without radiation can achieve long term remissions. Advanced diseases generally do not respond to multimodality therapy including immunotherapy but can have disease stabilization with variable survival. CDKN2A/B mutations were common and potentially associated with a worse outcome. Better understanding of the impact of the FDCS mutational landscape on prognosis may provide novel approaches to therapy. [Table: see text]
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
Bhansali, Rahul S. , Ellin, Fredrik , Relander, Thomas, Cao, Miao , Li, Wenrui , Long, Qi , Ganesan, Nivetha , Stuver, Robert , Wudhikarn, Kitsada, Sokol, Lubomir, Duan, Frank, Pullarkat, Priyanka, Mehta–Shah, Neha , Ruiz, Miguel , Brammer, Jonathan E. , Prakash, Rishab, Iyer, Swaminathan P. , Major, Ajay , Smith, Sonali M. , Goldin, Caroline, Haverkos, Bradley M. , Zhuang, Tony , Allen, Pamela B. , Toama, Wael , Janakiram, Murali , Brooks, Taylor , Jagadeesh, Deepa, Hariharan, Nisha , Goodman, Aaron M. , Hartman, Gabrielle, Fayyaz, Fatima , Gerson, James N. , Svoboda, Jakub , Long, Qi , Wudhikarn, Kitsada , Hwang, Steven R , Bennani, N Nora , Saeed, Hayder , Porcu, Pierluigi , Mehta-Shah, Neha , Zain, Jasmine , Olszewski, Adam J , Smith, Sonali M , Haverkos, Bradley M , Hu, Bei , Zhuang, Tony Z , Allen, Pamela Blair , Toama, Wael , Brooks, Taylor R , Ghione, Paola , Fayyaz, Fatima , Rhodes, Joanna , Chong, Elise A , Barta, Stefan K , Major, Ajay , Janakiram, Murali , Bhansali, Rahul S , Stuver, Robert , Horwitz, Steven M. , Hwang, Steven R. , Bennani, N. Nora , Chavez, Julio C , Olszewski, Adam J. , Riedell, Peter A. , Hu, Bei , Jagadeesh, Deepa , Hariharan, Nisha, Ghione, Paola , Rhodes, Joanna , Chong, Elise A. , Landsburg, Daniel J. , Nasta, Sunita , Schuster, Stephen J. , Jerkeman, Mats

Mayo Clinic

Blood Advances | May 13, 2024 | Volume: 8 | Issue: 13 | Pages: 3507-3518

10.1182/bloodadvances.2024012800 | PMID 38739715 Get It

Abstract Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS relapse in patients with MTNKN and developed the CNS relapse In T-cell lymphoma Index (CITI) to predict patients at the highest risk of CNS relapse. We reviewed data from 135 patients with MTNKN and CNS relapse from 19 North American institutions. After exclusion of leukemic and most cutaneous forms of MTNKNs, patients were pooled with non-CNS relapse control patients from a single institution to create a CNS relapse–enriched training set. Using a complete case analysis (n = 182), including 91 with CNS relapse, we applied a least absolute shrinkage and selection operator Cox regression model to select weighted clinicopathologic variables for the CITI score, which we validated in an external cohort from the Swedish Lymphoma Registry (n = 566). CNS relapse was most frequently observed in patients with peripheral T-cell lymphoma, not otherwise specified (25%). Median time to CNS relapse and median overall survival after CNS relapse were 8.0 and 4.7 months, respectively. We calculated unique CITI risk scores for individual training set patients and stratified them into risk terciles. Validation set patients with low-risk (n = 158) and high-risk (n = 188) CITI scores had a 10-year cumulative risk of CNS relapse of 2.2% and 13.4%, respectively (hazard ratio, 5.24; 95% confidence interval, 1.50-18.26; P = .018). We developed an open-access web-based CITI calculator (https://redcap.link/citicalc) to provide an easy tool for clinical practice. The CITI score is a validated model to predict patients with MTNKN at the highest risk of developing CNS relapse.
Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma
Desai, Aakash , Xiao, Alexander , Toruner, Merih Deniz , Walden, Daniel , Hálfdánarson, Þorvarður R. , Mahipal, Amit , Ahn, Daniel H. , Stybayeva, Gulnaz , Revzin, Alexander , Kizilbash, Sani H. , Adjei, Alex A. , Bekaii‐Saab, Tanios , Mansfield, Aaron S. , Carr, Ryan M. , Xiao, Alexander H , Choi, Daheui , Toruner, Merih D , Halfdanarson, Thorvardur R , Alberts, Steven, Mahipal, Amit , Stybayeya, Gulnaz , Kizilbash, Sani, Mansfield, Aaron S , Carr, Ryan M , Desai, Aakash P , Bekaii-Saab, Tanios S , Kizilbash, Sani H , Alberts, Steven R. , McWilliams, Robert R. , Babiker, Hani M. , Wee, Wen

Mayo Clinic

Cancers | May 13, 2024 | Volume: 16 | Issue: 10 | Pages: 1861

10.3390/cancers16101861 | PMID 38791940 Get It

Purpose: To investigate the molecular characteristics of and potential for precision medicine in KRAS wildtype pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: We investigated 27 patients with KRASWT PDAC at our institution. Clinical data were obtained via chart review. Tumor specimens for each subject were interrogated for somatic single nucleotide variants, insertion and deletions, and copy number variants by DNA sequencing. Gene fusions were detected from RNA-seq. A patient-derived organoid (PDO) was developed from a patient with a MET translocation and expanded ex vivo to predict therapeutic sensitivity prior to enrollment in a phase 2 clinical trial. Results: Transcriptomic analysis showed our cohort may be stratified by the relative gene expression of the KRAS signaling cascade. The PDO derived from our patient harboring a TFG-MET rearrangement was found to have in vitro sensitivity to the multi-tyrosine kinase inhibitor crizotinib. The patient was enrolled in the phase 2 SPARTA clinical trial and received monotherapy with vebrelitinib, a c-MET inhibitor, and achieved a partial and durable response. Conclusions: KRASWT PDAC is molecularly distinct from KRASMUT and enriched with potentially actionable genetic variants. In our study, transcriptomic profiling revealed that the KRAS signaling cascade may play a key role in KRASWT PDAC. Our report of a KRASWT PDAC patient with TFG-MET rearrangement who responded to a cMET inhibitor further supports the pursuit of precision oncology in this sub-population. Identification of targetable mutations, perhaps through approaches like RNA-seq, can help enable precision-driven approaches to select optimal treatment based on tumor characteristics.
Use of Deep Learning to Evaluate Tumor Microenvironmental Features for Prediction of Colon Cancer Recurrence
Sinicrope, Frank A. , Nelson, Garth D. , Saberzadeh-Ardestani, Bahar , Segovia, Diana I. , Graham, Rondell P. , Wu, Christina , Shivji, Sameer , Savage, Paul , Buchanan, Daniel D. , Phipps, Amanda I. , Swallow, Carol J. , Gallinger, Steven , Grant, Robert C. , Pai, Reetesh K. , Sinicrope, Stephen N. , Yan, Dongyao , Shanmugam, Kandavel , Conner, James , Cyr, David P. , Kirsch, Richard , Banerjee, Imon , Alberts, Steve R., Pai, Rish K. , Hagen, Catherine E , Shivji, Sameer , Savage, Paul , Buchanan, Daniel D , Jenkins, Mark A , Phipps, Amanda I , Swallow, Carol , Marchand, Loïc Le , Gallinger, Steven , Grant, Robert C , Pai, Reetesh K , Sinicrope, Stephen N , Yan, Dongyao , Shanmugam, Kandavel , Conner, James , Cyr, David P , Kirsch, Richard , Banerjee, Imon , Alberts, Steven R , Shi, Qian , Pai, R K , Graham, Rondell P , Sinicrope, Frank A , Wu, Christina , Hagen, Catherine E. , Jenkins, Mark A. , Marchand, Loı̈c Le , Alberts, Steven R. , Shi, Qian

Mayo Clinic

Cancer Research Communications | May 6, 2024 | Volume: 4 | Issue: 5 | Pages: 1344-1350

10.1158/2767-9764.crc-24-0031 | PMID 38709069 Get It

Abstract Deep learning may detect biologically important signals embedded in tumor morphologic features that confer distinct prognoses. Tumor morphologic features were quantified to enhance patient risk stratification within DNA mismatch repair (MMR) groups using deep learning. Using a quantitative segmentation algorithm (QuantCRC) that identifies 15 distinct morphologic features, we analyzed 402 resected stage III colon carcinomas [191 deficient (d)-MMR; 189 proficient (p)-MMR] from participants in a phase III trial of FOLFOX-based adjuvant chemotherapy. Results were validated in an independent cohort (176 d-MMR; 1,094 p-MMR). Association of morphologic features with clinicopathologic variables, MMR, KRAS, BRAFV600E, and time-to-recurrence (TTR) was determined. Multivariable Cox proportional hazards models were developed to predict TTR. Tumor morphologic features differed significantly by MMR status. Cancers with p-MMR had more immature desmoplastic stroma. Tumors with d-MMR had increased inflammatory stroma, epithelial tumor-infiltrating lymphocytes (TIL), high-grade histology, mucin, and signet ring cells. Stromal subtype did not differ by BRAFV600E or KRAS status. In p-MMR tumors, multivariable analysis identified tumor-stroma ratio (TSR) as the strongest feature associated with TTR [HRadj 2.02; 95% confidence interval (CI), 1.14–3.57; P = 0.018; 3-year recurrence: 40.2% vs. 20.4%; Q1 vs. Q2–4]. Among d-MMR tumors, extent of inflammatory stroma (continuous HRadj 0.98; 95% CI, 0.96–0.99; P = 0.028; 3-year recurrence: 13.3% vs. 33.4%, Q4 vs. Q1) and N stage were the most robust prognostically. Association of TSR with TTR was independently validated. In conclusion, QuantCRC can quantify morphologic differences within MMR groups in routine tumor sections to determine their relative contributions to patient prognosis, and may elucidate relevant pathophysiologic mechanisms driving prognosis. Significance: A deep learning algorithm can quantify tumor morphologic features that may reflect underlying mechanisms driving prognosis within MMR groups. TSR was the most robust morphologic feature associated with TTR in p-MMR colon cancers. Extent of inflammatory stroma and N stage were the strongest prognostic features in d-MMR tumors. TIL density was not independently prognostic in either MMR group.
Author response: Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Innocenti, Federico , Diasio, Robert B. , Largiadèr, Carlo R. , Offer, Steven M. , Largiadèr, Carlo R , Offer, Steven M , Bouchonville, Kelly J. , Wang, Zhiquan , Stroka, Deborah

Mayo Clinic

No container title available | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.3.sa2 Get It

Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Tine, Brian A. Van , Ingham, Matthew , Attia, Steven , Meyer, Christian F. , Baird, John D. , Brooks-Asplund, Esther M. , D'Silva, Dhiren, Kong, Ronald , Mwatha, Anthony, O’Keefe, Kylie, Weetall, Marla , Spiegel, Robert J. , Van Tine, Brian A , Ingham, Matthew A , Brooks-Asplund, Esther , Schwartz, Gary K , Meyer, Christian , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | April 29, 2024 | Volume: 42 | Issue: 20 | Pages: 2404-2414

10.1200/jco.23.01684 | PMID 38684039 Get It

PURPOSE This multicenter, single-arm, open-label, phase Ib study was designed to determine the recommended phase II dose (RP2D) and to evaluate the safety and preliminary efficacy of unesbulin plus dacarbazine (DTIC) in patients with advanced leiomyosarcoma (LMS). PATIENTS AND METHODS Adult subjects with locally advanced, unresectable or metastatic, relapsed or refractory LMS were treated with escalating doses of unesbulin orally twice per week in combination with DTIC 1,000 mg/m2 intravenously (IV) once every 21 days. The time-to-event continual reassessment method was used to determine the RP2D on the basis of dose-limiting toxicities (DLTs) assessed during the first two 21-day treatment cycles. All explored doses of unesbulin (200 mg up to 400 mg) were in combination with DTIC. An expansion cohort was enrolled to evaluate the safety and efficacy of unesbulin at the RP2D. RESULTS Unesbulin 300 mg administered orally twice per week in combination with DTIC 1,000 mg/m2 IV once every 21 days was identified as the RP2D. On the basis of data from 27 subjects who were deemed DLT-evaluable, toxicity was higher in the unesbulin 400 mg group, with three of four subjects (75%) experiencing DLTs versus one of four subjects (25%) in the 200 mg group and three of 19 subjects (15.8%) in the 300 mg group. The most commonly reported DLTs and treatment-related grade 3 and 4 adverse events were thrombocytopenia and neutropenia. At the RP2D, seven subjects who were efficacy evaluable achieved partial response for an objective response rate of 24.1%. CONCLUSION Unesbulin 300 mg twice per week plus DTIC 1,000 mg/m2 once every 21 days was identified as the RP2D, demonstrating a favorable benefit-risk profile in a heavily pretreated population of adults with advanced LMS.
Technical note: A comparison of in‐house 3D‐printed and commercially available patient‐specific skin collimators for use with electron beam therapy
Herchko, Steven, Rutenberg, Michael S. , Beltran, Chris , Yaddanapudi, Sridhar , Herchko, Steven M , Beltran, Chris J , Yaddanapudi, Sridhar

Mayo Clinic

Journal of Applied Clinical Medical Physics | April 26, 2024 | Volume: 25 | Issue: 5 | Pages: No page available

10.1002/acm2.14366 | PMID 38669190 Get It

AbstractPurposeSkin collimation is a useful tool in electron beam therapy (EBT) to decrease the penumbra at the field edge and minimize dose to nearby superficial organs at risk (OARs), but manually fabricating these collimation devices in the clinic to conform to the patient's anatomy can be a difficult and time intensive process. This work compares two types of patient‐specific skin collimation (in‐house 3D printed and vendor‐provided machined brass) using clinically relevant metrics.MethodsAttenuation measurements were performed to determine the thickness of each material needed to adequately shield both 6 and 9 MeV electron beams. Relative and absolute dose planes at various depths were measured using radiochromic film to compare the surface dose, flatness, and penumbra of the different skin collimation materials.ResultsClinically acceptable thicknesses of each material were determined for both 6 and 9 MeV electron beams. Field width, flatness, and penumbra results between the two systems were very similar and significantly improved compared to measurements performed with no surface collimation.ConclusionBoth skin collimation methods investigated in this work generate sharp penumbras at the field edge and can minimize dose to superficial OARs compared to treatment fields with no surface collimation. The benefits of skin collimation are greatest for lower energy electron beams, and the benefits decrease as the measurement depth increases. Using bolus with skin collimation is recommended to avoid surface dose enhancement seen with collimators placed on the skin surface. Ultimately, the appropriate choice of material will depend on the desire to create these devices in‐house or outsource the fabrication to a vendor.